Raymond James analyst Ryan Deschner raised the firm’s price target on Liquidia (LQDA) to $29 from $27 and keeps a Strong Buy rating on the shares. The firm expects Yutrepia to be approved on May 24, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Corporation Awaits FDA Decision on YUTREPIA
- Favorable Court Decision and Market Potential Propel Liquidia Technologies’ Buy Rating
- Liquidia reports Q1 EPS (45c) vs. (40c) last year
- Liquidia Technologies Updates Audit Report for March 2025
- Liquidia price target raised to $36 from $34 at Scotiabank